Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for severe primary IGF-1 deficiency, Alkindi Sprinkle for adrenal insufficiency, Khindivi for adrenocortical insufficiency, Galzin for Wilson disease, PKU Golike for phenylketonuria, Carglumic Acid for N-acetylglutamate synthase deficiency, Betaine Anhydrous for homocystinuria, and Nitisinone for tyrosinemia type 1. The company also has a pipeline of late-stage product candidates, such as ET-600 for diabetes insipidus, Amglidia for neonatal diabetes mellitus, ET-700 for Wilson disease, ET-800 for adrenal insufficiency, and the ZENEO hydrocortisone autoinjector for adrenal crisis.

Eton Pharmaceuticals, Inc. is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol ETON. Its shares are traded in United States Dollars (USD). The company is headquartered in Deer Park, Illinois, United States, and its primary market is the US stock exchange.

Eton Pharmaceuticals operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development and production of specialized pharmaceutical products, including treatments for rare diseases, as well as generic drugs. Its focus on rare diseases distinguishes it from large-scale generic manufacturers, as it targets niche therapeutic areas with high unmet medical needs.

Eton Pharmaceuticals, Inc. is headquartered in Deer Park, Illinois, United States. The company primarily serves the US market, as indicated by its listing on a US exchange and its focus on treatments approved by the US Food and Drug Administration (FDA). Its commercial products and pipeline candidates are aimed at addressing rare diseases within the United States healthcare system.

Eton Pharmaceuticals generates revenue by developing and commercializing treatments for rare diseases. Its business model involves acquiring or developing late-stage product candidates and bringing them to market. Key commercial products include Increlex (for severe primary IGF-1 deficiency), Alkindi Sprinkle (adrenal insufficiency), Khindivi (adrenocortical insufficiency), Galzin (Wilson disease), PKU Golike (phenylketonuria), Carglumic Acid (NAGS deficiency), Betaine Anhydrous (homocystinuria), and Nitisinone (tyrosinemia type 1). The company also has a pipeline of late-stage candidates such as ET-600 for diabetes insipidus and the ZENEO hydrocortisone autoinjector for adrenal crisis.